Suppr超能文献

[甲状腺功能亢进症的临床症状、诊断及药物治疗]

[Clinical aspects, diagnosis and drug therapy of hyperthyroidism].

作者信息

Bürgi U, Gerber H, Peter H J

机构信息

Abteilung für Endokrinologie und Diabetologie, Inselspital Bern.

出版信息

Schweiz Med Wochenschr. 1995 Aug 8;125(31-32):1489-94.

PMID:7545825
Abstract

Graves' disease and toxic uni- or multinodular goiter are the most frequent causes of hyperthyroidism. Graves' disease is caused by thyroid stimulating immunoglobulins which are directed against the TSH receptor of thyroid follicular cells. Graves' disease affects more females than males and is associated with diffuse goiter and a rapid appearance of symptoms and signs of hyperthyroidism. Patients with Graves' disease are on average younger than patients with toxic nodular goiter. The diagnosis of Graves' disease is usually easy, particularly if signs of endocrine opthalmopathy are present. Toxic nodular goiter is seen more often in older patients with pre-existing goiters. Symptoms and signs of hyperthyroidism often appear only slowly. Hyperthyroidism in these older patients can be oligosymptomatic. Older patients should therefore be investigated for the presence of hyperthyroidism, even if they present only a few symptoms or signs which could suggest this diagnosis. The development of ultrasensitive TSH assays has simplified the diagnosis of hyperthyroidism and made the TRH-test, often used in the past, almost superfluous. At the present time, it is practically always possible to differentiate between Graves' disease and toxic nodular goiter as the cause of hyperthyroidism on the basis of clinical and laboratory findings alone, and in many cases thyroid scintiscans are therefore no longer necessary. A patient with newly diagnosed Graves' disease is treated with antithyroid drugs (carbimazole or PTU) for one year. If hyperthyroidism persists after this one year of antithyroid drug treatment, or if it recurs, another year of therapy with carbimazole or PTU is indicated.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

格雷夫斯病和毒性单结节或多结节性甲状腺肿是甲状腺功能亢进最常见的病因。格雷夫斯病由针对甲状腺滤泡细胞促甲状腺激素(TSH)受体的甲状腺刺激免疫球蛋白引起。格雷夫斯病女性患者多于男性,与弥漫性甲状腺肿有关,且甲状腺功能亢进的症状和体征出现迅速。格雷夫斯病患者的平均年龄比毒性结节性甲状腺肿患者年轻。格雷夫斯病的诊断通常很容易,尤其是存在内分泌性眼病体征时。毒性结节性甲状腺肿在已有甲状腺肿的老年患者中更常见。甲状腺功能亢进的症状和体征往往出现得较慢。这些老年患者的甲状腺功能亢进可能症状较少。因此,即使老年患者仅表现出一些可能提示该诊断的症状或体征,也应进行甲状腺功能亢进的检查。超敏TSH检测方法的发展简化了甲状腺功能亢进的诊断,使过去常用的促甲状腺激素释放激素(TRH)试验几乎不再必要。目前,仅根据临床和实验室检查结果,几乎总能区分格雷夫斯病和毒性结节性甲状腺肿作为甲状腺功能亢进的病因,因此在许多情况下甲状腺闪烁扫描不再必要。新诊断的格雷夫斯病患者用抗甲状腺药物(卡比马唑或丙硫氧嘧啶)治疗一年。如果抗甲状腺药物治疗一年后甲状腺功能亢进仍持续存在,或复发,则需再用卡比马唑或丙硫氧嘧啶治疗一年。(摘要截取自250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验